Has Mark Osterman received payments from drug or device companies?

Yes. Drug and device makers reported $39,458 in general payments to Mark Osterman across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Osterman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Osterman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Osterman

Gastroenterology · Philadelphia, PANPI 1669526851

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $32,775 of the $39,458 with a category attached, or 83.1%. 7 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 36.8% of the total. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,458in general payments, 2019–2025

Across 31 payments — averaging $1272.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$15K
Johnson & Johnson$12K
Pfizer$4K
F. Hoffmann-la Roche AG$4K
Bristol Myers Squibb$3K
AbbVie$651
plus $15 from 1 others

$373,750in research payments, 2019–2025

Across 58 payments — averaging $6443.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$222K
Takeda Pharmaceuticals U.S.A., Inc.$104K
AbbVie$44K
Pfizer$4K

What the payments were for

Consulting fees$32,77583%
Speaking & faculty fees$4,91612%
Travel & lodging$1,3123%
Food & beverage$4451%
Education$100%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	7	$14,507
Johnson & Johnson	15	$12,379
Pfizer	4	$4,480
F. Hoffmann-la Roche AG	1	$4,050
Bristol Myers Squibb	1	$3,375
AbbVie	2	$651
Shire North American Group Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

STELARA$12,091
Entyvio$10,446
XELJANZ$4,470
ZEPOSIA$3,375
Humira$600

How this compares

$39,458 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania →

Other gastroenterology in Philadelphia

Michael KochmanPhiladelphia$361K
Gary LichtensteinPhiladelphia$342K
Gregory GinsbergPhiladelphia$234K
Neilanjan NandiPhiladelphia$209K
David LichtensteinPhiladelphia$192K
Alexander SchlachtermanPhiladelphia$188K
Kuchikala ReddyPhiladelphia$182K
James LewisPhiladelphia$175K
Beth GardnerPhiladelphia$122K
Gary FalkPhiladelphia$121K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →